<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648814</url>
  </required_header>
  <id_info>
    <org_study_id>REC6100321</org_study_id>
    <nct_id>NCT03648814</nct_id>
  </id_info>
  <brief_title>Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT</brief_title>
  <official_title>Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospect studying the efficacy and safety of treating NVG with the intracameral versus the
      intravitreal injection of Bevacizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection
      via the intracameral route versus the intravitreal route in treating the neovascular glaucoma
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>regression of nevolascularization</measure>
    <time_frame>2 months</time_frame>
    <description>Amount of nevolascular of iris and angle regression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP reduction</measure>
    <time_frame>2 months</time_frame>
    <description>IOP reduction at 2-month visit compare to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection complication</measure>
    <time_frame>2 days</time_frame>
    <description>Hyphema, IOP spike</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Glaucoma, Neovascular</condition>
  <condition>Vascular Endothelial Growth Factor Overexpression</condition>
  <arm_group>
    <arm_group_label>Intracameral injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracameral injection</intervention_name>
    <description>A/C injection of 1.25 mg/0.05 mL bevacizumab</description>
    <arm_group_label>Intracameral injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injection</intervention_name>
    <description>Vitreous injection of 1.25 mg/0.05 mL bevacizumab</description>
    <arm_group_label>Intravitreal injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of neovascular glaucoma

          2. The patients having IOP &gt; 21 mmHg, having the indication for trabeculectomy

          3. The patients' age of at least 18-year-old

          4. The patients having visual potential at least hand motion.

          5. Present of NVI or NVA.

          6. Willing and able to provide informed consent to participate in the study

          7. Able to understand the purpose of the study, his/her role, and is available to return
             to the clinic/hospital for all required follow-up visits

        Exclusion Criteria:

          1. One eye patient

          2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view.

          3. Cannot obtain endothelial cell count.

          4. History of bevacizumab or fluorescence dye allergy.

          5. Active infectious ocular disease including endophthalmitis and corneal ulcer

          6. History of systemic disease including ischemic heart disease, cerebrovascular disease,
             end-stage renal disease, liver failure, uncontrolled hypertension

          7. Has or planning to be pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assoc.Prof.Weerawat Kiddee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Songkla University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assoc.Prof.Weerawat Kiddee, MD</last_name>
    <phone>+66874954626</phone>
    <email>kweerawat@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University</name>
      <address>
        <city>Hat-yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WEERAWAT KIDDEE, MD</last_name>
      <phone>66-81271-0644</phone>
      <email>kweerawat@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Weerawat Kiddee</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>Neovascular glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

